Receptor, Fibroblast Growth Factor, Type 1
"Receptor, Fibroblast Growth Factor, Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fibroblast growth factor receptor with specificity for FIBROBLAST GROWTH FACTORS; HEPARAN SULFATE PROTEOGLYCAN; and NEURONAL CELL ADHESION MOLECULES. Several variants of the receptor exist due to multiple ALTERNATIVE SPLICING of its mRNA. Fibroblast growth factor receptor 1 contains three extracellular IMMUNOGLOBULIN C2-SET DOMAINS and is a tyrosine kinase that transmits signals through the MAP KINASE SIGNALING SYSTEM.
| Descriptor ID |
D051496
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.177 D12.776.543.750.630.440 D12.776.543.750.750.400.370.500
|
| Concept/Terms |
Receptor, Fibroblast Growth Factor, Type 1- Receptor, Fibroblast Growth Factor, Type 1
- FGFR1 Protein
- Fibroblast Growth Factor Receptor 1
- fms-Like Tyrosine Kinase-2
- fms Like Tyrosine Kinase 2
- CD331 Antigen
- Antigen, CD331
- FGFR1 Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Fibroblast Growth Factor, Type 1".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, Fibroblast Growth Factor, Type 1 [D08.811.913.696.620.682.725.400.177]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- Receptor, Fibroblast Growth Factor, Type 1 [D12.776.543.750.630.440]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Fibroblast Growth Factor [D12.776.543.750.750.400.370]
- Receptor, Fibroblast Growth Factor, Type 1 [D12.776.543.750.750.400.370.500]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Fibroblast Growth Factor, Type 1".
This graph shows the total number of publications written about "Receptor, Fibroblast Growth Factor, Type 1" by people in this website by year, and whether "Receptor, Fibroblast Growth Factor, Type 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, Fibroblast Growth Factor, Type 1" by people in Profiles.
-
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb; 8:e2300513.
-
Leptomeningeal Dissemination of Low-Grade Neuroepithelial Tumor with FGFR1_TACC1 Fusion with Clinical and Radiographic Response to Pazopanib and Topotecan. Pediatr Neurosurg. 2022; 57(1):63-68.
-
Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer. Clin Cancer Res. 2021 08 01; 27(15):4379-4396.
-
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clin Cancer Res. 2020 11 15; 26(22):5974-5989.
-
Baseline Computed Tomography Radiomic and Genomic Assessment of Head and Neck Squamous Cell Carcinoma. J Comput Assist Tomogr. 2020 Jul/Aug; 44(4):546-552.
-
Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. Clin Cancer Res. 2020 01 15; 26(2):354-363.
-
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 10; 14(10):1847-1852.
-
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Invest New Drugs. 2020 04; 38(2):457-467.
-
Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation. J Pathol. 2018 09; 246(1):54-66.
-
Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance. Genome Med. 2018 05 23; 10(1):37.